

Surfaxin[®](lucinactant)
Intratracheal Suspension

» ABOUT SURFAXIN

» FAQ BOOK

» CONTACT US

» DOWNLOADABLE TOOLS

SURFAXIN[®], THE ONLY AVAILABLE**SYNTHETIC ALTERNATIVE** TO
ANIMAL-DERIVED SURFACTANTS
APPROVED BY THE FDA*Join the Therapeutic Evolution...***Read More****FULL PRESCRIBING INFORMATION****WARMING CRADLE[®] USER'S MANUAL**

Step-by-Step Guide

**DOSING CHART**

A Quick Reference for SURFAXIN Dosing

**MONOGRAPH**

A Comprehensive SURFAXIN Review

First U.S. FDA approved alternative to surfactants made with animal extract in more than 20 years⁵Neonatologists and parents share concerns regarding animal-derived medications⁴Direct clinical comparisons to Exosurf[®], Surfacta[®] and Curosurf[®]^{1,2}

SURFAXIN (lucinactant) Intratracheal Suspension is approved by the U.S. Food and Drug Administration (FDA) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for developing RDS.

IMPORTANT SAFETY INFORMATION

SURFAXIN[®] (lucinactant) Intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.

SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see full prescribing information

Sinapultide (KL4 peptide) mimics critical surfactant protein B function³Therapeutic precision from manufacturing through preparation to dosing¹Supportive health economics data⁶**VIDEOS****SURFAXIN Administration Video**

5:00

**WARMING CRADLE[®] Instructional Video**

4:08

THE SURFAXIN[®] APP

Keep all of your SURFAXIN resources at your finger tips with a free app for your iPhone[®], iPad[®], or Android[®].

Get the Apps

ABOUT SURFAXIN

ABOUT DISCOVERY LABS

CONTACT US

DOWNLOADABLE TOOLS

Surfaxin.

Exosurf®
Exosurf®
Exosurf®

ABOUT SURFAXIN

FAQ BOOK

CONTACT US

DOWNLOADABLE TOOLS

FULL PRESCRIBING INFORMATION

WARMING CRADLE® USER'S MANUAL

Warming Cradle®

DOSING CHART

Quick Reference to SURFAXIN Dosing


MONOGRAPH

A Comprehensive SURFAXIN Review

SURFAXIN®, THE ONLY AVAILABLE


Concerns About Animal-Derived Products

Neonatologists
n=98



92% of neonatologists expressed concerns over exposure of newborn infants to animal-derived medicines

Parents of infants in the NICU
n=150



67% of parents want to be informed if an animal-derived medicine is to be administered to their newborn

Sarkar S, Donn SM. Do neonatologists and parents share the same concerns about animal-derived pharmaceutical agents? J of Neonatal Perinatal Medicine. 2011;4(3):235-239.

developing RDS.

IMPORTANT SAFETY INFORMATION

SURFAXIN (Exosurf) intratracheal suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.

SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see full prescribing information

*This website provides basic information through presentation of data.

Supportive health economics data®



Direct clinical comparisons to Exosurf®, Surfactant®, and Curosurf®

VIDEOS



SURFAXIN Administration Video



WARMING CRADLE® Instructional Video

THE SURFAXIN® APP

Keep all of your SURFAXIN resources at your finger tips with a free app for your iPhone®, iPad®, or Android®.

Get the Apps



ABOUT SURFAXIN

ABOUT DISCOVERY LABS

CONTACT US

DOWNLOADABLE TOOLS

Surfaxin.

Surfactant
ventilator Surfactant

ABOUT SURFAXIN

FAQ BOOK

CONTACT US

DOWNLOADABLE TOOLS

FULL PRESCRIBING INFORMATION

WARMING CRADLE® USER'S MANUAL

Warming Cradle®

DOSING CHART


Quick Reference to SURFAXIN Dosing

MONOGRAPH

A Comprehensive SURFAXIN Review

SURFAXIN®, THE ONLY AVAILABLE

Comparison of SP-B or SP-B mimic (KL₄) as a Percent of Phospholipid Across Commercially Available Surfactants



¹Curosurf® (poractant alfa) Intratracheal Suspension [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; 2009.

²Infasurf® (calfactant) Intratracheal Suspension [prescribing information]. Amherst, NY: Ony Inc; 2009.

³Survanta® (beractant) Intratracheal Suspension [prescribing information]. North Chicago, IL: AbbVie Inc; 2012.

⁴Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids. 2002;114(1):21-34.

⁵SURFAXIN® (lucinactant) Intratracheal Suspension [prescribing information]. Warrington, PA: Discovery Laboratories Inc; 2012.

developing RDS.

IMPORTANT SAFETY INFORMATION

SURFAXIN® (lucinactant) intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.

SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see full prescribing information

ABOUT SURFAXIN

ABOUT DISCOVERY LABS

CONTACT US

DOWNLOADABLE TOOLS

Direct clinical comparisons to Exosurf®, Survanta®, and Curosurf®

VIDEOS



SURFAXIN Administration Video



WARMING CRADLE® Instructional Video

THE SURFAXIN® APP

Keep all of your SURFAXIN resources at your finger tips with a free app for your iPhone®, iPad®, or Android®.

Get the Apps

Surfaxin®

(lucinactant)
synthetic surfactant

ABOUT SURFAXIN

FAQ BOOK

CONTACT US

DOWNLOADABLE TOOLS

SURFAXIN®, THE ONLY AVAILABLE

SYNTHETIC ALTERNATIVE TO ANIMAL-DERIVED SURFACTANTS APPROVED BY THE FDA

Join the Therapeutic Evolution...

Read More

Unlike animal-derived surfactants that are made with surfactant proteins extracted from animal lung, SURFAXIN® is a synthetic, peptide-containing surfactant manufactured to ensure a consistent level of SP-B mimic (KL4) is delivered with each recommended dose.(1)

1. SURFAXIN® (lucinactant) Intratracheal Suspension [prescribing information]. Warrington, PA: Discovery Laboratories Inc; 2012.

FULL PRESCRIBING INFORMATION

WARMING CRADLE® USER'S MANUAL

Warming Cradle®

DOSING CHART

Quick Reference to SURFAXIN Dosing

MONOGRAPH

A Comprehensive SURFAXIN Review



First U.S. FDA approved alternative to surfactants made with animal extract in more than 20 years *



Neonatologists and parents share concerns regarding animal-derived medications *



Direct clinical comparisons to Exosurf®, Surfactant®, and Curosurf® *

SURFAXIN (lucinactant) Intratracheal Suspension is approved by the U.S. Food and Drug Administration (FDA) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for developing RDS.

IMPORTANT SAFETY INFORMATION

SURFAXIN (lucinactant) intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.

SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see [full prescribing information](#)

Prevalence of respiratory distress syndrome (RDS) in premature *

Therapeutic potential from exogenous therapy through prematurity to delivery *

Supportive health economics data *

VIDEOS



SURFAXIN Administration Video



WARMING CRADLE® Instructional Video

THE SURFAXIN® APP

Keep all of your SURFAXIN resources at your finger tips with a free app for your iPhone®, iPad®, or Android®.

Get the Apps



ABOUT SURFAXIN

ABOUT DISCOVERY LABS

CONTACT US

DOWNLOADABLE TOOLS